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HIGHLIGHTS
• Vapor nanobubble (VNB) photoporation represents a promising physical technique for mRNA transfection of adherent and suspension cells.
• A multitude of parameters related to the VNB photoporation procedure were optimized to enable efficient mRNA transfection.
• VNB photoporation was found to yield five times more living, transfected Jurkat T cells as compared to electroporation, i.e., currently 
the standard nonviral transfection technique for T cells.
ABSTRACT Efficient and safe cell engineering by transfection of nucleic acids 
remains one of the long-standing hurdles for fundamental biomedical research and 
many new therapeutic applications, such as CAR T cell-based therapies. mRNA 
has recently gained increasing attention as a more safe and versatile alternative 
tool over viral- or DNA transposon-based approaches for the generation of adop-
tive T cells. However, limitations associated with existing nonviral mRNA deliv-
ery approaches hamper progress on genetic engineering of these hard-to-transfect 
immune cells. In this study, we demonstrate that gold nanoparticle-mediated vapor 
nanobubble (VNB) photoporation is a promising upcoming physical transfection 
method capable of delivering mRNA in both adherent and suspension cells. Initial 
transfection experiments on HeLa cells showed the importance of transfection 
buffer and cargo concentration, while the technology was furthermore shown to be 
effective for mRNA delivery in Jurkat T cells with transfection efficiencies up to 45%. Importantly, compared to electroporation, which is the 
reference technology for nonviral transfection of T cells, a fivefold increase in the number of transfected viable Jurkat T cells was observed. 
Altogether, our results point toward the use of VNB photoporation as a more gentle and efficient technology for intracellular mRNA delivery in 
adherent and suspension cells, with promising potential for the future engineering of cells in therapeutic and fundamental research applications.
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1 Introduction
In recent years, mRNA has gained immense interest as a 
novel class of nucleic acid therapeutics [1–3]. In contrast 
to DNA therapeutics, mRNA does not require nuclear 
entry to be functional, being translated instantly after 
reaching the cell cytoplasm and thus avoiding potential 
insertional mutagenesis. In addition, mRNA-based thera-
peutics have a reduced risk of long-term side effects as 
they are only transiently active inside the cell. The afford-
ability and ease of production have furthermore advanced 
the development of mRNA as a versatile class of nucleic 
acid therapeutics, while inherent obstacles such as unfa-
vorable immunogenicity and short half-life time were 
addressed [1, 2, 4, 5]. Driven by these advances, mRNA 
has also emerged as a promising tool for ex vivo engi-
neering of adoptive T cells [2]. For this, patient-derived 
T cells are expanded ex vivo and engineered for targeted 
cytotoxicity against cancer or viral-infected cells, prior 
to re-injection into the patient. Recently, the first two chi-
meric antigen receptor (CAR) T cell products, i.e., Kym-
riah™ (tisagenlecleucel; Novartis) [6] and Yescarta™ 
(axicabtagene ciloleucel; Kite Pharma, Gilead) [7, 8], 
have been approved by the US Food and Drug Admin-
istration (FDA) [9, 10]. Genetic modification of the T 
cells is performed using engineered viruses carrying a 
vector with the tumor antigen-specific CAR. The use of 
these viral vectors, however, comes with the limitations 
of being costly, time-consuming and often having vari-
able results [11–13]. In addition, persistent expression 
of the CAR construct and risk of insertional mutagenesis 
contributes to their unfavorable safety profile [11]. While 
DNA transposons, e.g., sleeping beauty transposon, are 
considered as a safer nonviral approach, the risk of per-
sistent side effects and insertional mutagenesis remains. 
mRNA, with its inherent safety features and ease of use, 
has therefore been raised as a promising alternative over 
viral- or transposon-based methods for the generation of 
adoptive T cells [2, 14]. Gene editing by transient Cas9 
mRNA expression, for example, became of interest to 
facilitate highly efficient therapeutic T cell engineering, 
while reducing the risk of off-target effects and overcom-
ing DNA-related cytotoxicity [15, 16].
The success of mRNA in cell-based immunotherapy 
strongly relies on the ability to efficiently deliver the mRNA 
molecules to target immune cells. Of note, improving the effi-
ciency of current transfection technologies is also expected 
to strongly impact the scalability and production cost of 
cell-based therapies [5]. Many different technologies have 
emerged over the years to address the ever recurring issue of 
intracellular delivery of mRNA, though each of them faces 
divergent limitations. mRNA is a large negatively charged, 
single-stranded nucleic acid that can be encapsulated in syn-
thetic nanocarriers for protection against ubiquitous serum 
nucleases and enhancing endocytic uptake [17]. Gold nano-
particles, for example, have been extensively studied as drug 
and gene delivery carriers because of their favorable phys-
icochemical properties [18–24]. However, carrier-induced 
cytotoxicity and low transfection efficiency are common dis-
advantages for T cells [3]. Physical delivery methods have 
recently gained attention when it comes to in vitro and ex vivo 
cell modification, featuring a broad applicability on different 
cell types and cargos [17, 25]. Electroporation, which makes 
use of strong electric fields to deliver nucleic acids to the cell 
interior, is currently the preeminent tool for mRNA trans-
fections of hard-to-transfect immune cells [2, 26]. It should 
be noted, however, that electroporation was amply shown 
to come with significant loss of cell viability, induction of 
unwanted phenotypic changes or loss of cell functionality [17, 
27–30]. Laser-assisted photoporation, sometimes also referred 
to as optoporation, recently came up as a promising gentler 
technique for intracellular delivery of biological macromol-
ecules [23, 24, 31]. Wayteck et al., for instance, previously 
showed in a one-on-one comparison between photoporation 
and electroporation on murine T cells that a threefold higher 
percentage of siRNA-transfected viable cells was obtained by 
photoporation as it induced much less cytotoxicity compared 
to electroporation [32].
In its most straightforward form, photoporation is 
obtained by focusing high-intensity femtosecond laser pulses 
onto the cell membrane, thereby inducing very local mem-
brane permeabilization and allowing extracellular molecules 
to enter the cell cytoplasm [31]. It has been shown to enable 
efficient mRNA transfection in primary rat neurons even 
on a subcellular level [33, 34], as well in single neurons 
of zebrafish embryos [35]. Although proven effective for 
single-cell transfections, its general usability is limited by 
low-throughput and labor-intensive procedures. The former 
can, however, be substantially increased by making addi-
tional use of photothermal nanoparticles. After attaching to 
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the cell membrane and applying laser irradiation, they can 
very locally disturb cell membrane integrity. The advantage 
over traditional photoporation is that these nanoparticles 
substantially reduce the required light density to enhance 
membrane permeability, thus allowing to use broad laser 
beams and resulting in an immensely increased photopora-
tion throughput [36]. In addition, photothermal effects can 
be efficiently achieved with much less expensive nanosecond 
pulsed lasers. A particularly effective photothermal phenom-
enon for creating transient pores in the cell membrane is 
the generation of vapor nanobubbles (VNBs). These VNBs 
nucleate from the nanoparticles, such as plasmonic gold nan-
oparticle (AuNPs), by the rapid evaporation of the immedi-
ate surrounding liquid upon pulsed laser irradiation, while 
heat diffusion to the environment is negligible [37–39]. In 
addition to AuNPs, graphene-based nanoparticles [40], car-
bon black nanoparticles [41] and different types of metal 
alloys [42] have also been suggested for the same purpose. 
By rapid expansion and subsequent collapse of the VNB 
after absorption of a laser pulse, high-pressure shockwaves 
and fluid shear stress can cause physical damage to the 
neighboring cell membrane structures. In turn, this results 
in the formation of very localized and transient membrane 
pores, allowing extracellular cargo to passively diffuse into 
the cell interior [32, 38, 43, 44]. Conveniently, the technique 
can be applied to both adherent cells [38] and suspension 
cells [32, 44], while it is compatible with any type of trans-
parent cell recipient (e.g., culture flasks, multiwell plates). 
Furthermore, it offers the possibility to transfect even single 
cells in high throughput [45, 46].
While VNB photoporation has been demonstrated to 
be suitable to transfect a broad variety of cell types with 
many different cargos like siRNA [32, 38], nanobodies 
[40] and other proteins [43], we here report for the first 
time its suitability for the intracellular delivery of mRNA. 
Since mRNA is a considerably large (between 20–200 nm), 
highly negative charged macromolecule compared to 
smaller antisense oligonucleotides or proteins (between 
1–20 nm), effective intracellular delivery of these mole-
cules across the negatively charged cell membrane is par-
ticularly challenging [17]. We performed experiments on 
HeLa and Jurkat T cells as models for adherent and suspen-
sion cells. Jurkat T cells serve as a valid model for primary 
human T cells [47] and are routinely used for screening and 
optimization of CAR constructs [48–52]. We started by 
systematically optimizing several parameters related to the 
VNB photoporation procedure, including AuNP concentra-
tion, laser fluence and transfection buffer. We found that 
for HeLa cells transfection efficiencies up to 38% could be 
obtained while maintaining a high level of cell viability. 
In Jurkat T cells, transfection efficiencies up to 20% could 
be obtained, which could be further enhanced to 45% by 
applying the procedure up to three times. These results 
were compared to mRNA transfections by electropora-
tion, which is currently the method of choice for nonviral 
genetic engineering of T cells. Electroporation appeared to 
be extremely toxic to Jurkat T cells leading to a reduction 
by ~ 95% of the metabolic activity of the treated cells, even 
though in the 5% viable cells very high transfection effi-
ciencies were obtained. Hence, VNB photoporation yielded 
five times more transfected viable Jurkat T cells as com-
pared to electroporation. Altogether, this study establishes 
VNB photoporation as a promising, more gentle approach 
for mRNA transfections of adherent and suspension cells, 
which is expected to be beneficial for both research and 
therapeutic purposes.
2  Material and Methods
2.1  Materials
Dulbecco’s modified Eagle’s medium containing growth fac-
tor F-12 (DMEM/F-12), Roswell Park Memorial Institute 
1640 (RPMI-1640), Opti-MEM, L-Glutamine, Dulbecco’s 
phosphate-buffered saline with  Ca2+/Mg2+ (DPBS+) or 
without  Ca2+/Mg2+ (DPBS−), penicillin/streptomycin solu-
tion (5000 IU/mL penicillin and 5000 μg/mL streptomycin), 
0.25% trypsin–EDTA solution, fetal bovine serum (FBS), 
Hoechst33342, TO-PRO3 iodide (1 mM), CellMask Deep 
red stain, CellTrace Far Red stain and RNA millennium™ 
marker were purchased from Life Technologies (Merelbeke, 
Belgium). CleanCap (cc) enhanced green fluorescent protein 
(eGFP) and cc Renilla Luciferase (RLuc) mRNA (5′ moU) 
were received from TriLink Biotechnologies (San Diego, Cal-
ifornia, USA) and stored at  −  80 °C until use. 60 nm AuNPs 
were synthesized and coated in-house with the cationic poly-
mer poly(diallyldimethylammonium chloride) (PDDAC), as 
previously described [24, 43, 44]. Physicochemical properties 
of the AuNPs were reported before by Raes et al., with a mean 
zeta potential of + 42 mV, average core diameter of 58 nm and 
average hydrodynamic size of 113 nm [44].
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2.2  In vitro Transcription of MLKL‑mRNA
Murine MLKL-encoding mRNA was produced using a 
pIVTstab-MLKL template, as designed by Van Hoecke 
et al. [53]. The plasmid was first linearized by a PstI restric-
tion digest (Promega, Leiden, the Netherlands), following 
purification using a QIAquick PCR purification kit (Qiagen, 
Chatsworth, CA, USA). MLKL-mRNA was obtained by 
in vitro transcription with the mMESSAGE mMACHINE™ 
T7 ULTRA Transcription Kit (Life Technologies, Merel-
beke, Belgium), according to the manufacturer’s instruc-
tions. The in vitro transcribed MLKL-mRNA was eventually 
purified by LiCl precipitation and stored at − 80 °C until 
further use.
2.3  Cell Culture
HeLa cells (cervical adenocarcinoma cells, ATCC® CCL-
2™) were cultured in DMEM/F-12 supplemented with 
10% FBS, 2 mM L-glutamine, and 100 μg/mL penicillin/
streptomycin. Cells were seeded at a density of 5 × 103 cells/
well of a µ-slide angiogenesis (ibidi GmbH, Martinsried, 
Germany) and incubated for 24 h at 37 °C, 5%  CO2 prior 
to photoporation. µ-slides angiogenesis are compatible with 
high-resolution microscopy while allowing good attachment 
of adherent cells thanks to a cell culture-compatible polymer 
coating. Jurkat E6-1 (human leukemic T cells, ATCC® TIB-
152™) and B16F10 cells (murine melanoma cells, ATCC® 
CRL-6475™) were cultured in RPMI-1640 medium supple-
mented with 10% FBS, 2 mM L-glutamine and 100 µg/mL 
penicillin/streptomycin. B16F10 cells were seeded at a den-
sity of 25 × 103 cells/well of a 96-well plate and incubated at 
37 °C, 5%  CO2 prior to transfection. Jurkat E6-1 cells were 
maintained in a humidified atmosphere of 5%  CO2 at 37 °C, 
and the culture medium was renewed every 2–4 days. On 
the day of transfection, 250 × 103 Jurkat E6-1 cells were first 
incubated with AuNPs, next washed with culture medium 
(see Sect. 2.5) and eventually transferred to a 96-well plate 
for photoporation treatment.
2.4  Analysis of mRNA Integrity by Agarose Gel 
Electrophoresis
mRNA integrity after incubation with HeLa cells, either 
with or without a prior washing step with Opti-MEM, was 
assessed by native agarose gel electrophoresis. Prior to addi-
tion of the mRNA, the cells were washed once with DPBS, 
followed by an Opti-MEM washing step of 10 min (only 
for specified samples). Next, eGFP-mRNA was diluted in 
Opti-MEM to a final concentration of 0.3 µM and incubated 
on the cells for the specified time (5, 10, 20, or 30 min). 
mRNA diluted in Opti-MEM, mRNA incubated with 
10 µg/ml RNAseA (Ambion, Merelbeke, Belgium) and a 
0.5–10 kb RNA millennium™ marker were taken along as 
controls. The samples were loaded on a 1% agarose gel, and 
gel electrophoresis was performed at 100 V for 30 min. For 
visualization of the mRNA integrity, a Bio-Rad UV transil-
luminator 2000 (Hercules, CA, USA) was used.
2.5  Visualization and Quantification of AuNP 
Attachment
Cells were washed once with DPBS (HeLa) or culture 
medium (Jurkat, 250 × 103 cells) and incubated with AuNP 
in culture medium for 30 min at 37 °C. Next, the cells were 
washed once with DPBS (HeLa) or culture medium (Jur-
kat) and supplemented with new culture medium. AuNP 
attachment to the cells was visualized by confocal reflec-
tion microscopy (C1si or C2, Nikon BeLux, Brussels, Bel-
gium) using a 60× water immersion lens (Plan Apo, NA 
1.2, Nikon BeLux, Brussels, Belgium). Jurkat cells were 
additionally incubated with CellMask deep red (1000×) 
and Hoechst33342 (1000×) for 10 min at 37 °C to stain 
the cell membrane and nucleus, respectively. HeLa cells 
were first incubated with CellTrace Far Red (500×) for 
20 min at 37 °C to stain the cytoplasm, after which they 
were washed twice with culture medium and incubated 
with Hoechst33342 for 10 min at 37 °C. After staining, 
the cells were washed with culture medium and imaged 
using confocal microscopy. Image analysis was performed 
using the ImageJ software (FIJI, https ://Fiji.sc/), includ-
ing merging the different fluorescent or reflection images 
into a composite and dilation of the AuNP scattering sig-
nal (HeLa), to visualize and quantify the number of cell-
attached AuNPs. For each AuNP concentration and each 
independent experiment, a minimum of 50 (HeLa) or 150 
(Jurkat E6-1) cells were analyzed for AuNP attachment by 
combination of multiple confocal reflection microscopy 
images recorded for different AuNP incubation samples 
(≥ 2 wells).
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2.6  Determination of the VNB Generation Threshold
A previously reported in-house developed optical setup 
was used to determine the laser pulse fluence threshold 
[24, 38], which is defined as the laser fluence of a single 
laser pulse at which 90% of the irradiated AuNPs generate 
a VNB. In short, 60 nm AuNPs (stock: ~  4 × 1010 AuNPs 
 mL−1) were first diluted 50× in  ddH2O and transferred 
to a 50 mm γ-irradiated glass bottom dish (MatTek Cor-
poration, Ashland, MA, USA). After sedimentation, the 
AuNPs sample was mounted on an inverted microscope 
(TE2000, Nikon BeLux, Brussels, Belgium) and irradi-
ated with a pulsed laser (~  7 ns) tuned at a wavelength of 
561 nm (Opolette™ HE 355 LD, OPOTEK Inc, Carlsbad, 
CA, USA). The laser beam diameter at the sample was 
150 µm. The laser pulse energy was monitored using an 
energy meter (LE, Energy Max-USB/RS sensors, Coher-
ent). An electronic pulse generator (BNC575, Berkeley 
Nucleonics Corporation) triggered individual laser pulses 
and synchronized an EMCCD camera (Cascade II: 512, 
Photometrics) to record dark-field microscopy images 
before, during and after VNB formation. VNB can be seen 
distinctly in dark-field microscopy images as brief bright 
localized flashes of light, due to the increase in light scat-
tering during their lifetime. By quantifying the number of 
visible VNBs within the laser pulse area (150 µm diam-
eter) for increasing laser pulse fluences, the VNB genera-
tion threshold was determined.
2.7  mRNA Transfection by VNB Photoporation
Cells were incubated with AuNPs at different concentra-
tions, as described above. After washing away unbound 
AuNPs, cells were incubated with Opti-MEM for 10 min 
as it proved to be beneficial to minimize mRNA degra-
dation. Next, cells were photoporated in the presence of 
mRNA diluted in the indicated transfection buffer. Opti-
MEM, DMEM/F-12, DPBS+  and DPBS were all used 
as transfection buffer in various experiments. After laser 
treatment, the cells were supplemented with fresh cell 
culture medium and allowed to settle for 6 h (RLuc) or 
24 h (eGFP) prior to analysis of mRNA expression or cell 
viability.
2.8  Transfection of Jurkat Cells by Nucleofection
Jurkat cells were transfected with eGFP-mRNA using a 
4D-Nucleofector™ according to the manufacturer’s rec-
ommendations with the SE Cell line 4D-Nucleofector kit 
(V4XC-1032) (Lonza, Breda, the Netherlands). First, 2 × 105 
Jurkat cells together with 2 µg eGFP-mRNA were resus-
pended in 20 µL SE cell line solution and transferred to a 
16-well Nucleocuvette™ strip. The cells were transfected 
using the pulse program CL-120 and immediately after sup-
plemented with 80 µL preheated culture medium. Finally, 
50 µL of that cell suspension was transferred to a 96-well 
plate already containing 150 µL preheated culture medium 
and incubated at 37 °C, 5%  CO2 for 24 h prior to analysis by 
confocal microscopy, flow cytometry and viability assays.
2.9  Analysis of eGFP Expression by Confocal 
Microscopy and Flow Cytometry
Efficiency of eGFP-mRNA transfection was visualized by 
confocal microscopy (C1si, Nikon BeLux, Brussels, Bel-
gium) using a 10 × objective lens (Plan Apo, NA 0.45) or 
60× water immersion lens (Plan Apo, NA 1.2, Nikon BeLux, 
Brussels, Belgium). Quantification of the percentage eGFP-
positive cells was performed by flow cytometry using a 
CytoFLEX flow cytometer (Beckman Coulter, Suarlée, 
Belgium). The resulting flow cytometry data were analyzed 
using FlowJo (Treestar Inc, Ashland, USA) software.
2.10  Analysis of RLuc mRNA Expression
Efficiency of RLuc mRNA expression was determined 6 h 
after VNB photoporation using the Renilla-Glo™ Luciferase 
assay system (Promega, Leiden, the Netherlands). In short, 
50 × 103 Jurkat cells in 50 µL culture medium were combined 
with an equal volume of Renilla-Glo™ Luciferase Assay Rea-
gent. After 10 min, the luminescent signal was measured using 
a GloMax™ luminometer (Promega, Leiden, the Netherlands). 
The luminescent signal of each condition was background sub-
tracted (wells with reagent but no cells) and normalized rela-
tive to the untreated control.
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2.11  CellTiter‑Glo® Viability Assay
Viability of HeLa, B16F10 cells or Jurkat cells was assessed 
for 18 h (B16F10) or 24 h (HeLa, Jurkat) after VNB photo-
poration or nucleofection using the CellTiter-Glo® lumines-
cent cell viability assay, as recommended by the manufacturer 
(Promega, Leiden, the Netherlands). Briefly, HeLa, B16F10 
and Jurkat cells were supplemented with an equal volume of 
CellTiter-Glo® reagent for each well, mixed for 5–10 min 
using an orbital shaker (120 rpm) and transferred to an opaque 
96-well plate. After allowing the plate to stabilize for 10 min, 
the luminescent signal of each well was measured using a 
GloMax™ luminometer (Promega, Leiden, the Netherlands).
2.12  Evaluation of Cell Viability and Cell Proliferation 
by Trypan Blue Cell Counting
HeLa cells were first harvested by trypsinization (0.25% 
trypsin/EDTA), following neutralization with cell cul-
ture medium. HeLa or Jurkat cell density in each condi-
tion was assessed using a Bürker counting chamber (Brand 
GMBH + CO KG, Wertheim, Germany) and trypan blue 
exclusion (0.4%, Sigma-Aldrich, Overijse, Belgium). Cell 
viability of the different samples was calculated relatively to 
their respective untreated control. Cell growth was normal-
ized against the untreated control at day 0 and followed for 
up to 5 days.
2.13  Statistical Analysis
All data are shown as mean ± standard deviation, unless 
stated differently. Statistical differences were analyzed using 
the GraphPad Prism 8 software (La Jolla, CA, USA). The 
statistical tests used in each figure are mentioned in the fig-
ure caption. Statistical differences with a p value < 0.05 were 
considered significant.
3  Results
3.1  VNB Photoporation Procedure for mRNA 
Transfection
In this study, we investigated the applicability of VNB 
photoporation using 60  nm cationic PDDAC-coated 
AuNPs as photothermal nanoparticles for mRNA trans-
fection. AuNPs with a diameter of 60 nm were previously 
described to be ideal photothermal sensitizers, requiring a 
minimum bubble nucleation threshold laser fluence [54]. 
The experimental procedure for mRNA transfection by 
VNB photoporation is illustrated in Fig. 1a. For transfec-
tion by VNB photoporation, cells are first incubated with 
cationic AuNPs that will be adsorbed to the cell surface. 
After washing away unbound AuNPs, irradiation with a 
single laser pulse (7 ns) leads to the generation of VNBs 
arising from the cell-bound AuNPs. The inevitable col-
lapse of the VNBs when the thermal energy is consumed 
causes local pore formation in the cell membrane, allow-
ing extracellular mRNA molecules to diffuse through 
these membrane pores directly into the cytoplasm. Effec-
tive generation of these VNBs can be visualized using 
dark-field microscopy as a result of an increased amount 
of light scattering during their lifetime (Fig. S1a). Upon 
laser irradiation and subsequent VNB generation, the 
AuNPs are known to fragment into smaller pieces that 
scatter less light. These AuNP fragments are therefore not 
visible anymore in the laser-irradiated region [23, 40]. By 
quantification of the number of generated VNBs within 
a defined laser irradiated area as a function of the laser 
fluence (i.e., energy per unit area), the so-called VNB gen-
eration threshold fluence was assessed (Fig. S1b). This 
value is defined as the fluence at which VNBs are formed 
with 90% certainty and was, in good agreement with pre-
viously reported work [44], determined to be 0.9 J cm−2.
Considering the inherent labile nature of naked mRNA, 
premature degradation of these nucleic acids prior to 
transfection can easily take place. To test this, a native 
agarose gel electrophoresis assay was performed to quali-
tatively evaluate the physical integrity of the mRNA after 
incubation on the cells (Fig. 1b). As we observed that five 
minutes of incubation of the mRNA solution on HeLa 
cells already resulted in complete mRNA degradation, 
an Opti-MEM washing step for 10 min prior to the addi-
tion of mRNA to the cells was included to wash away 
any remaining RNAses as much as possible. After that, 
the mRNA remained intact for at least 10 min, which 
is sufficient as the photoporation procedure only lasts 
~ 3 min. This washing step was, therefore, included in all 
further experiments before performing the photoporation 
procedure.
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3.2  mRNA Transfection of Adherent Cells by VNB 
Photoporation
To date, the applicability of nanoparticle-sensitized photo-
poration for transfection of mRNA has not yet been investi-
gated. The HeLa human epithelial adenocarcinoma cell line 
served here as a reference cell type for initial optimization, 
as it has already previously been used extensively to quantify 
intracellular delivery of a wide range of molecules (e.g., 
siRNA and nanobodies) by VNB photoporation [38, 40, 
55]. Different parameters related to the VNB photoporation 
procedure were optimized to reach maximum transfection 
efficiency with acceptable cytotoxicity, including AuNP 
concentration, laser fluence, transfection buffer and mRNA 
concentration. In concordance with the vast majority of sci-
entific studies on adherent cell lines, a cytotoxicity threshold 
level of 80% was chosen for HeLa cell experiments.
First, different AuNP concentrations and laser fluences 
were screened for transfection efficiency and cell viability. 
Cells were incubated for 30 min with AuNP concentrations of 
4, 8, and 16 × 107 AuNPs  mL−1 (Fig. 2a). After washing, this 
led to ~ 3 ± 1 AuNPs, 5 ± 1 AuNPs and 10 ± 2 AuNPs per cell 
on average (mean ± SD), as determined by confocal reflec-
tion microscopy (Fig. S2). Next, laser irradiation (561 nm) 
was applied such that every cell in the sample essentially 
received a single laser pulse of 1.8 J cm−2, which is about 
twice the VNB generation threshold for these gold nanopar-
ticles and therefore ensures effective VNB generation [44]. 
Using 0.3 µM eGFP-mRNA, up to 21% eGFP-positive cells 
were obtained depending on the AuNP concentration. At the 
same time, a slight drop in cell viability was seen 24 h after 
photoporation, as measured by the CellTiter-Glo assay and 
further confirmed by a trypan blue cell counting assay (Fig. 
S3). When considering 20% loss of metabolic activity as a 
commonly chosen acceptable level of cytotoxicity, 8 × 107 
AuNPs  mL−1 (~ 5 AuNPs/cell) was selected as the most opti-
mal concentration, yielding about 16% eGFP-positive cells. 
Higher laser fluences were previously suggested to result in 
bigger VNBs and membrane pores [38] and could therefore 
further enhance the delivery efficiency of these high molecu-
lar weight mRNA molecules. Using the previously optimized 






































Fig. 1  Optimized procedure for mRNA transfection by vapor nanobubble (VNB) photoporation. a Schematic illustration of the VNB photopo-
ration procedure for mRNA transfection. b Analysis of physical mRNA integrity by native agarose gel electrophoresis; 1 µg eGFP-mRNA was 
incubated on HeLa cells for the specified amount of time, either with or without a prior washing step with Opti-MEM. As controls, mRNA incu-
bated only in Opti-MEM (Opti-MEM ctrl) or incubated for 30 min with 10 µg mL−1 RNAse A (RNAse A ctrl) was included
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evaluated, i.e., one (0.9 J cm−2), twice (1.8 J cm−2) and four 
times (3.6 J cm−2) the VNB generation threshold fluence. 
A moderately increasing trend in eGFP-mRNA transfection 
efficiency was indeed observed with increasing laser fluences 
(Figs. 2b and S4), resulting in up to 20% eGFP-positive cells 
at a laser fluence of 3.6 J cm−2, while cell viability remained 
> 80% for all conditions. Based on these results, it was 
chosen to continue with an AuNP concentration of 8 × 107 
AuNPs  mL−1 and laser fluence of 3.6 J cm−2 for further VNB 
photoporation experiments on HeLa cells.
Next, we investigated the influence of transfection buffer 
on eGFP-mRNA transfection efficiency, which reportedly 
can greatly influence cell viability and transfection efficiency 
of physical transfection methods [17]. Therefore, we per-
formed photoporation experiments on HeLa cells in different 
commercially available buffers or media, including Opti-
MEM, Dulbecco’s phosphate buffered saline with (DPBS+) 
or without  Ca2+/Mg2+ (DPBS−) or DMEM/F-12. Confocal 
microscopy images showed that transfection efficiency was 
highest for DPBS+ (Fig. 3a). This could be quantitatively 
confirmed by flow cytometry, with a 1.55-fold increase in 
the number of transfected cells as compared to Opti-MEM 
(Fig. 3b), while cell viability remained > 80% (Fig. 3c). 
Based on these results, DPBS + was selected as transfection 
buffer for all further transfections of HeLa cells.
Next, we evaluated the effect of increasing the mRNA 
concentration (0.3, 0.9, and 1.5 µM). As can be seen from 
the flow cytometry data in Fig. 4a, the percentage of eGFP-
positive cells increased for higher mRNA concentrations, 
reaching up to 38% eGFP-positive cells for 1.5 µM mRNA. 
This trend is furthermore illustrated in Fig. 4b, showing 
contour plots that display eGFP expression 24 h after a rep-
resentative mRNA transfection experiment. Taken together, 
the results above provide a first proof-of-concept on the 
applicability of VNB photoporation for intracellular deliv-
ery of mRNA. Moreover, extensive optimization of different 
parameters related to the photoporation procedure allowed 
to obtain favorable mRNA transfection efficiencies of up 
to 38%.
Finally, to provide further proof that successful mRNA 
transfections are not limited to the eGFP-mRNA used so 
far, we proceeded with the transfection of murine MLKL 
(mixed lineage kinase domain-like)-encoding mRNA 
in B16F10 murine melanoma cells. MLKL is a known 
necroptosis executioner, i.e., a type of immunogenic cell 
death, so that MLKL-mRNA transfection is expected to 
cause decreased cell viability [53]. Optimized VNB pho-
toporation conditions for B16F10 cells were previously 
determined by our group, as reported by Van Hoecke & 
Raes et al. [43]. The results in Fig. S5 show that a signifi-
cant drop in cell viability of 17% is obtained after transfec-
tion of MLKL-encoding mRNA in comparison with the 
VNB photoporation control without MLKL-mRNA. This 
level of mRNA transfection is in line with our expectations, 
given that eGFP-mRNA transfection efficiencies of ~ 16% 
are obtained in HeLa cells using similar VNB photopora-
tion conditions (0.3 µM, 8 × 107 AuNPs  mL−1, 1.8 J cm−2). 
With these results, we demonstrated the applicability of the 
VNB photoporation technology for intracellular delivery 






























































































Fig. 2  Optimization of gold nanoparticle (AuNP) concentration and laser fluence for eGFP-mRNA transfection in HeLa cells. a HeLa cells were 
photoporated in the presence of 0.3 µM eGFP-mRNA with increasing AuNP concentrations using a fixed laser fluence of 1.8 J cm−2. b HeLa 
cells were photoporated in the presence of 0.3 µM eGFP-mRNA with increasing laser fluences using a fixed AuNP concentration of 8 × 107 
AuNPs  mL−. Transfection efficiencies are expressed as the percentage eGFP-positive cells as determined by flow cytometry (n ≥ 3). Cell viabil-
ity values were determined with the CellTiter-Glo assay and expressed relatively to the untreated control (n = 3). One-way ANOVAs with Dun-
nett’s multiple comparison test were performed to determine statistical differences (ns = nonsignificant; *p < .05; **p < .01; ***p < .001)
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3.3  Transfection of Jurkat T Cells with eGFP‑mRNA 
by VNB Photoporation
The Jurkat E6-1 human leukemic T cell line was used here 
as a model for primary human T cells [47]. Analogous to the 
HeLa cell transfection experiments, different key parameters 
in the VNB photoporation procedure were first optimized for 
Jurkat cells (Fig. 5), i.e., (1) AuNP concentration, (2) laser 
fluence and (3) transfection buffer.
Jurkat cells were first incubated for 30 min with increas-
ing AuNP concentrations, ranging from 1 to 16 × 107 
AuNPs  mL−1. Using confocal reflection microscopy, it 
was found that the corresponding number of cell-attached 
AuNPs ranged from ~ 1 to ~ 5 AuNP/cell (Fig. S6). After 
transfection by VNB photoporation with a laser fluence of 
1.8 J cm−2, again an increasing percentage of eGFP-positive 
cells was obtained for increasing AuNP concentrations, with 
a concomitant decrease in cell viability (Fig. 5a). Eventually 
aimed at producing therapeutic engineered patient-derived 
T cells, in this case it is of interest to re-express these data 
as the percentage of transfected living cells. Indeed, lim-
ited T cell numbers are typically collected from profoundly 
lymphopenic patients owing to multiple previous rounds 

















































Fig. 3  Screening of transfection buffers for mRNA transfection in HeLa cells. HeLa cells were transfected with eGFP-mRNA by VNB pho-
toporation (0.3  µM mRNA; 8 × 107 AuNPs  mL−1; 3.6  J  cm−2) using different transfection buffers: Opti-MEM (OM), DPBS−, DPBS+ or 
DMEM/F-12. a Representative confocal microscopy images of HeLa cells 24 h after transfection (Scale bar = 150 µm). b Transfection efficiency 
ratios for different buffers compared to OM, as measured by flow cytometry (n = 6). A one-way ANOVA with Dunnett’s multiple comparison 
test was performed to determine statistical differences between OM and the other buffers (ns = nonsignificant; ****p < .0001). c Cell viability 
24 h post transfection, expressed relatively to the untreated control (n = 3). A one-way ANOVA with Dunnett’s multiple comparison test was per-
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Fig. 4  Influence of increasing eGFP-mRNA concentrations on transfection efficiency. a Transfection efficiencies, expressed as the percentage 
eGFP-positive cells, for different concentrations of eGFP-mRNA (n = 3). b Contour plots of a representative experiment on HeLa cells trans-
fected with increasing concentrations of eGFP-mRNA
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production yield of viable, engineered T cells. As the data 
show in Fig. 5b, an optimum is found for 4 × 107 AuNPs 
 mL−1 (~ 2 AuNPs/cell) at which ~ 13% of the initial cell 
population is viable and transfected. In the next section, we 
will put these results in perspective against transfection by 
electroporation.
As a next step, different laser fluences were tested using 
a fixed AuNP concentration of 4 × 107 AuNPs  mL−1. eGFP 
expression was evaluated both qualitatively by confocal 
microscopy (Fig. S7) and quantitatively by flow cytom-
etry (Fig.  5c, d). The percentage of positive cells did 
not increase with the laser fluence, but cell viability did 
decrease slightly (Fig. 5c). As a result, the best yield of 
living and transfected cells (~ 14%) was obtained for the 
lowest laser fluence of 0.9 J cm−2 (Fig. 5d). When evaluat-
ing the effect of different transfection buffers, contrary to 
HeLa cells, DPBS+ did not enhance eGFP-mRNA trans-
fection of Jurkat cells (Fig. 5e, f). Therefore, we chose to 
continue further experiments on Jurkat cells using Opti-
MEM as transfection buffer. These optimized conditions 
were furthermore shown to enable effective Luc mRNA 
transfection of Jurkat cells (Fig. S8).
Until this point, the most optimal conditions has led 
to 75% viable Jurkat cells of which 20% are transfected 
with eGFP-mRNA. This means that after applying one 
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Fig. 5  Optimization of gold nanoparticle (AuNP) concentration, laser fluence and transfection buffer for eGFP-mRNA transfection in Jurkat 
cells. Transfection efficiencies represent the percentage of eGFP-positive cells, cell viability values were calculated relatively to the untreated 
control and yields are calculated as the product of transfection efficiency and cell viability. a, b Screening for AuNP concentrations, using a 
fixed laser fluence of 1.8 J cm−2 (n = 3, one-way ANOVA with Dunnett’s multiple comparison test, ns = nonsignificant; *p < .05, ***p < .001). 
c, d Screening for laser fluences (in J  cm−2), using a fixed AuNP concentration of 4 × 107 AuNPs  mL−1 (n = 3, one-way ANOVA with Dunnett’s 
multiple comparison test, ns = nonsignificant; *p < .05, **p < .01). e, f Comparison of Opti-MEM (OM) and DPBS + as transfection buffer, using 
a fixed AuNP concentration of 4 × 107 AuNPs  mL−1 and laser fluence of 0.9 J cm−2 (n = 3, unpaired Student’s T test, ns = nonsignificant)
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Jurkat cells that are alive but untransfected. As such, it is 
of interest to try to repeat the photoporation procedure 
to see whether that can further enhance the final yield of 
living transfected cells. Figure 6 shows the results for 1× , 
2×  and 3× photoporation of Jurkat cells. Between each of 
the procedures, cells were allowed to recover for 30 min, 
after which cells were again incubated with AuNP for 
30 min and washed with Opti-MEM before photoporating 
again with eGFP-mRNA. After 2× photoporation, there 
remained 61% viable cells, of which now 33% are positive 
for eGFP. Repeating photoporation for a third time led to 
45% viable cells, of which 45% was positive for eGFP. 
These results are summarized in Fig. 6b, showing for each 
repetition the fraction of nonviable (grey), viable untrans-
fected (blue) and viable transfected (green) cells. Repeat-
ing photoporation two times increased the transfected cell 
yield significantly to 20% (p < 0.05). Repeating photopo-
ration a third time did not produce a net beneficial effect 
as the increase in the number of transfected living cells is 
compensated for by an increase in cell death as well.
3.4  VNB Photoporation Produces More Living 
mRNA‑Transfected Jurkat Cells than Nucleofection
Electroporation is currently the most common nonviral tech-
nique for transfection of nucleic acids and ex vivo modification 
of T cells [9]. Having previously optimized the VNB photo-
poration procedure for mRNA transfection of Jurkat cells, we 
here compared our technology with nucleofection as a state-
of-the-art commercial electroporation system (Fig. 7). Nucle-
ofection of Jurkat cells was performed using the optimized 
protocol from the manufacturer (Pulse code: CL-120; SE cell 
line solution); 24 h after transfection, a drastic impact on cell 
viability was observed with only 4% viable cells (Fig. 7a), 
which is in concordance with several other studies on trans-
fection of lymphocytes by electroporation [27, 28]. Nearly all 
of those (98%) were transfected with eGFP-mRNA, leading to 
final yield of 4% living transfected cells after electroporation 
(Fig. 7b). This is about 5 × less as what we obtained with the 
two times repeated photoporation procedure.
In addition to acute cytotoxicity shortly after transfec-
tion, nucleofection was previously shown to significantly 
impact on the long-term behavior of T cells [28]. For this, 
we here extended the comparison between VNB photopo-
ration and nucleofection by follow-up of the cell viabil-
ity (Fig. 7c, d) and cell proliferation (Fig. 7e, f) up to 
5 days after Jurkat T cell transfection. While cell viabil-
ity remained favorable (> 60%) for VNB photoporation 
5 days post-transfection, no improvement in cell viabil-
ity was observed for cells transfected by nucleofection. 
We furthermore found no significant difference in cell 
growth between the untreated cells and photoporated cells, 
whereas no sign of recovery was observable even 5 days 
post-nucleofection. Altogether, these data put VNB pho-
toporation forward as a more gentle approach for mRNA 







































































Fig. 6  Effect of multiple consecutive VNB photoporation treatments on mRNA transfection efficiency of Jurkat cells. a Transfection efficiencies 
represent the percentage of eGFP-positive cells, and cell viability values were calculated relatively to the untreated control. b Viable/transfected, 
viable/untransfected and dead cell populations were calculated for the different conditions (n ≥ 3, One-way ANOVA with Tukey’s multiple com-
parison test, *p < .05, ns = nonsignificant)
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4  Discussion
In the last few years, cell-based therapeutics such as 
CAR T cells have emerged as a very promising approach 
for the treatment for hematological malignancies [13]. 
In 2020, over 500 clinical trials employing CARs have 
been reported worldwide, which clearly highlights the 
enthusiasm for adoptive cell therapies [56]. The success of 
T cell-based therapies, however, strongly depends on the 
ability to engineer these immune cells [9, 57]. Viral vec-
tors are currently the clinical and commercial standard for 
this purpose, but they face multiple issues such as immu-
nogenicity, high cost and variable outcomes. Indeed, trans-














































































































































Fig. 7  Comparison of nucleofection and VNB photoporation for mRNA transfection in Jurkat cells. a Jurkat cells were transfected with eGFP-
mRNA (0.3 µM) by nucleofection according to the manufacturer instructions. The transfection efficiency (i.e., % eGFP-positive cells) and cell 
viability by a CellTiter-Glo assay were determined 24 h post-transfection (n = 3). b Comparison of nucleofection and VNB photoporation in 
terms of viable, transfected cell yield (n ≥ 3, unpaired Student’s T test; ****p < .0001). c, d Cell viability after VNB photoporation (c) or nucleo-
fection (d) was measured at different time points for 5 days post-transfection. On day 0, cell viability was determined 2 h post-transfection. Cell 
viability values were calculated relatively to the untreated control on each day (n = 2 × 3). e, f Normalized cell growth after VNB photoporation 
(e) or nucleofection (f) was measured at different time points for 5 days post-transfection. The normalized cell growth values were calculated 
relatively to the untreated control at day 0. Data are represented as the mean ± SEM (n = 2 × 3, unpaired Student’s T tests; ns = nonsignificant, 
***p < .001, ****p < .0001)
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to over 80% in reported clinical trials [58–60]. As a con-
sequence, mRNA-based cell therapies have come up as 
a safer and cheaper alternative to viral transductions [2].
In this work, we report for the first time on the use of 
VNB photoporation as a promising physical technique 
for gentle but efficient mRNA transfections. In its most 
common implementation, VNB photoporation harnesses 
a combination of plasmonic gold nanoparticles attached 
to the cell membrane and laser irradiation to transiently 
generate membrane pores and enable intracellular delivery 
of macromolecules. An incubation step of 30 min was pre-
viously found convenient to get the AuNPs well positioned 
for VNB photoporation, being either endocytosed but still 
in close proximity of the cell membrane (e.g., HeLa) or 
adsorbed to the cell membrane (e.g., Jurkat) [38, 44]. This 
AuNP incubation alone did not cause any significant cyto-
toxicity, which is in line with previously reported work on 
comparable AuNPs showing no impairment of cell viabil-
ity or long-term cell homeostasis [23, 38]. At first, we 
evaluated and systematically optimized the VNB photopo-
ration procedure for transfection of mRNA in the adherent 
HeLa cell line as a proof-of-concept. Several characteris-
tics of mRNA make its intracellular delivery challenging, 
including their relatively large size, strong negative charge 
and susceptibility to degradation by nucleases [17]. The 
latter was indeed something we encountered in our study as 
well. Even though nucleotide-modified mRNA was used, 
gel electrophoresis clearly showed rapid degradation of 
mRNA within a few minutes after addition to the cultured 
cells [61]. This prompted us to include an extra washing 
step to remove remaining serum nucleases, which could 
prevent mRNA degradation for at least 10 min. While this 
is still quite short, it is sufficient to carry out the photopo-
ration procedure which only took ~ 3 min. Based on earlier 
reports in the literature on the influence of the transfec-
tion buffer [17, 62], we also tried out different buffers for 
photoporation. We found that the percentage of transfected 
HeLa cells could be increased by a factor of ~ 1.5 using 
DPBS+ (containing  Ca2+ and  Mg2+) as transfection buffer 
instead of Opti-MEM. While supplementation with  Ca2+ 
has been suggested to influence membrane repair kinetics 
[17, 63], we rather hypothesize that  Ca2+ and  Mg2+ may 
bind to mRNA, resulting in a reduced electrostatic repul-
sion between the mRNA molecules and the cell membrane. 
This is because the same enhanced effect of DPBS + was 
not observed for mRNA transfection of Jurkat cells which 
indeed have a lower density of negatively charged gly-
cosaminoglycans on their cell membrane [44, 64]. Anal-
ogous to other physical transfection approaches, VNB 
photoporation locally disturbs the integrity of the plasma 
membrane and allows direct access to the cell cytoplasm. 
Once membrane pores are formed, mRNA molecules have 
only a short period of time (seconds to minutes) to reach 
the cell cytoplasm before membrane integrity is restored. 
Translocation of mRNA molecules to the cell cytoplasm 
is mainly thought to occur by passive diffusion during the 
pore lifetime [31]. For this, higher concentrations of the 
mRNA molecules were thought to increase the probability 
of mRNA molecules reaching the cytoplasm. Indeed, the 
percentage eGFP-positive cells reached up to 38% when 
using an mRNA concentration of 1.5 µM.
In the field of T cell-based therapeutics, the Jurkat T cell 
line is a frequently used model for primary human T cells 
[47]. Jurkat cells are, for instance, routinely used for ini-
tial in vitro screenings of novel CAR or engineered T cell 
receptor designs. A method that enables efficient and quick 
screening of different CAR constructs, without the need for 
designing a new dedicated viral vector for each construct, is 
therefore highly desirable [48–52, 65]. As a consequence, we 
selected the Jurkat T cell line to deliver the proof-of-concept 
that photoporation holds promise for the production of engi-
neered T cells by mRNA transfections. Considering that high 
levels of transfection efficiency and cell recovery are both 
essential in the manufacturing of clinical-grade adoptive T 
cells [9], we expressed our transfection data in terms of the 
percentage of transfected, living cells. We demonstrated that 
photoporation could produce 14% transfected, living Jurkat 
cells. In addition, we showed that repeating the photopora-
tion procedure a second time increased the transfected, liv-
ing cell yield further to 20%. Most notably, this was fivefold 
more than what was obtained with nucleofection as a state-
of-the-art electroporation technology. This is primarily due 
to the vast difference in the level of cytotoxicity induced by 
both techniques. Indeed, 24 h after treatment the metabolic 
activity of electroporated Jurkat cells had dropped dramati-
cally to only ~ 4%, while this remained over 60% after two 
consecutive photoporation treatments. These results are in 
line with previous work on siRNA transfection of murine 
T cells [32], where photoporation yielded three times more 
living transfected cells as compared to electroporation.
Although electroporation was previously proven success-
ful for mRNA transfection of T cells with efficiencies > 90% 
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[66–69], more recent studies have raised the striking issue 
of extremely high acute cytotoxicity [27, 28], as we also 
showed here. Moreover, we demonstrated that Jurkat cells 
did not recover even 5 days post-nucleofection, whereas the 
cells treated by VNB photoporation maintained their prolif-
erative potential. Apart from acute cytotoxicity, loss of func-
tionality and nonspecific and unintentional changes in the 
cellular phenotype have been reported before as disadvan-
tages of electroporation [27, 28]. These unfavorable effects 
were also shown to negatively influence the survival and 
in vivo potency of T cells to suppress tumor growth [27, 70]. 
At the same time, injection of nonviable T cells upon adop-
tive cell transfer can elicit immune responses and promote 
toxicity in vivo [71]. Spurred by the positive findings in our 
study, it will therefore be of interest to investigate the use 
of VNB photoporation for mRNA transfection of primary 
human T cells and its influence on T cell homeostasis and 
therapeutic functionality.
5  Conclusion
Gold nanoparticle-mediated VNB photoporation proves to 
be a promising approach for safe and efficient intracellu-
lar mRNA delivery in both adherent and suspension cells. 
After rigorous optimization of different parameters, a good 
balance between mRNA transfection efficiency and cell sur-
vival was obtained. Most importantly, comparison of VNB 
photoporation and electroporation for mRNA transfection 
of Jurkat T cells indicated a marked fivefold increase in the 
percentage of transfected living cells for photoporation. 
These results position the VNB photoporation technology as 
a promising, more gentle approach toward safe and efficient 
engineering of T cells.
Acknowledgements Funding by the European Research Council 
(ERC) under the European Union’s Horizon 2020 research and 
innovation program (Grant No. 648124) is acknowledged with 
gratitude. S.S. acknowledges the support of a VLAIO Grant (Grant 
Number: HBC.2017.0542.). J.C.F. (FWO Grant 1210120 N), J.V.H 
(FWO-SB grant 1S62519N) and R.X. (FWO Grants 1500418 N 
and 12Q8718N) gratefully acknowledge the financial support by 
the Flemish Research Foundation. L.V.H. is a junior assistant of the 
Department of Biomedical Molecular Biology. We thank the center 
for advanced light microscopy at Ghent University (Belgium) for 
the use and support of the microscopy experiments.
Authors’ contributions L.R., K.R. and K.B. conceived the study. 
L.R. did the investigation. L.R., K.R. and K.B. contributed to 
project administration. J.C.F., T.B., G.G., S.D.M., L.V.H., R.V., 
J.V.H., R.X., X.S. and B.V. contributed resources. S.S., S.D.S., 
K.R. and K.B. were responsible for supervision. L.R. was involved 
in writing—original draft. L.R., S.S., J.C.F., T.B., G.G., S.D.M., 
L.V.H., R.V., J.V.H., R.X., X.S., B.V., S.D.S., K.R. and K.B were 
involved in writing—review and editing.
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, 
as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and 
indicate if changes were made. The images or other third party 
material in this article are included in the article’s Creative Com-
mons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Com-
mons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain 
permission directly from the copyright holder. To view a copy of 
this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4082 0-020-00523 -0) contains 
supplementary material, which is available to authorized users.
References
 1. U. Sahin, K. Karikó, Ö. Türeci, mRNA-based therapeutics-
developing a new class of drugs. Nat. Rev. Drug Discov. 13, 
759–780 (2014). https ://doi.org/10.1038/nrd42 78
 2. J.B. Foster, D.M. Barrett, K. Karikó, The emerging role of 
in vitro-transcribed mRNA in adoptive T cell immunother-
apy. Mol. Ther. 27, 747–756 (2019). https ://doi.org/10.1016/j.
ymthe .2019.01.018
 3. Y. Granot-Matok, E. Kon, N. Dammes, G. Mechtinger, D. 
Peer, Therapeutic mRNA delivery to leukocytes. J. Control. 
Release 305, 165–175 (2019). https ://doi.org/10.1016/j.jconr 
el.2019.05.032
 4. S.V. Lint, D. Renmans, K. Broos, H. Dewitte, I. Lentacker 
et al., The ReNAissanCe of mRNA-based cancer therapy. 
Expert Rev. Vaccines 14, 235–251 (2015). https ://doi.
org/10.1586/14760 584.2015.95768 5
 5. J. Devoldere, H. Dewitte, S.C. De Smedt, K. Remaut, Evad-
ing innate immunity in nonviral mRNA delivery: don’t shoot 
the messenger. Drug Discov. Today 21, 11–25 (2016). https 
://doi.org/10.1016/j.drudi s.2015.07.009
 6. S.L. Maude, T.W. Laetsch, J. Buechner, S. Rives, M. Boyer 
et al., Tisagenlecleucel in children and young adults with 
B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–
448 (2018). https ://doi.org/10.1056/NEJMo a1709 866
 7. S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D.B. 
Miklos et al., Axicabtagene ciloleucel CAR T-cell therapy 
in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 
Nano-Micro Lett.          (2020) 12:185  Page 15 of 17   185 
1 3
2531–2544 (2017). https ://doi.org/10.1056/NEJMo a1707 
447
 8. S.J. Schuster, J. Svoboda, E.A. Chong, S.D. Nasta, A.R. 
Mato et al., Chimeric antigen receptor T cells in refractory 
B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017). 
https ://doi.org/10.1056/NEJMo a1708 566
 9. A. Aijaz, M. Li, D. Smith, D. Khong, C. Leblon et al., Bio-
manufacturing for clinically advanced cell therapies. Nat. 
Biomed. Eng. 2, 362–376 (2018). https ://doi.org/10.1038/
s4155 1-018-0246-6
 10. M.S. Goldberg, Improving cancer immunotherapy through 
nanotechnology. Nat. Rev. Cancer 19, 587–602 (2019). https 
://doi.org/10.1038/s4156 8-019-0186-9
 11. B.L. Levine, J. Miskin, K. Wonnacott, C. Keir, Global 
manufacturing of CAR T cell therapy. Mol. Ther. Meth-
ods Clin. Dev. 4, 92–101 (2017). https ://doi.org/10.1016/j.
omtm.2016.12.006
 12. J. Tchou, Y. Zhao, B.L. Levine, P.J. Zhang, M.M. Davis 
et al., Safety and efficacy of intratumoral injections of chi-
meric antigen receptor (CAR) T cells in metastatic breast 
cancer. Cancer Immunol. Res. 5, 1152–1161 (2017). https 
://doi.org/10.1158/2326-6066.CIR-17-0189
 13. X. Wang, I. Rivière, Clinical manufacturing of CAR T cells: 
foundation of a promising therapy. Mol. Ther. Oncolytics 3, 
16015 (2016). https ://doi.org/10.1038/mto.2016.15
 14. J.B. Foster, N. Choudhari, J. Perazzelli, J. Storm, T.J. 
Hofmann et al., Purification of mRNA encoding chimeric 
antigen receptor is critical for generation of a robust T-cell 
response. Hum. Gene Ther. 30, 168–178 (2018). https ://doi.
org/10.1089/hum.2018.145
 15. A. Hendel, R.O. Bak, J.T. Clark, A.B. Kennedy, D.E. Ryan 
et al., Chemically modified guide RNAs enhance CRISPR-
Cas genome editing in human primary cells. Nat. Biotech-
nol. 33, 985–989 (2015). https ://doi.org/10.1038/nbt.3290
 16. Q. Gao, X. Dong, Q. Xu, L. Zhu, F. Wang, Y. Hou, C. Chao, 
Therapeutic potential of CRISPR/Cas9 gene editing in engi-
neered T-cell therapy. Cancer Med. 8, 4254–4264 (2019). 
https ://doi.org/10.1002/cam4.2257
 17. M.P. Stewart, R. Langer, K.F. Jensen, Intracellular delivery by 
membrane disruption: mechanisms, strategies, and concepts. 
Chem. Rev. 118, 7409–7531 (2018). https ://doi.org/10.1021/
acs.chemr ev.7b006 78
 18. C. Bao, J. Conde, E. Polo, P. del Pino, M. Moros et al., A 
promising road with challenges: where are gold nanoparticles 
in translational research? Nanomedicine 9, 2353–2370 (2014). 
https ://doi.org/10.2217/nnm.14.155
 19. J. Conde, C. Bao, Y. Tan, D. Cui, E.R. Edelman et al., Dual tar-
geted immunotherapy via in vivo delivery of biohybrid RNAi-
peptide nanoparticles to tumour-associated macrophages and 
cancer cells. Adv. Funct. Mater. 25, 4183–4194 (2015). https 
://doi.org/10.1002/adfm.20150 1283
 20. J. Conde, F. Tian, Y. Hernandez, C. Bao, P.V. Baptista et al., 
RNAi-based glyconanoparticles trigger apoptotic pathways for 
in vitro and in vivo enhanced cancer-cell killing. Nanoscale 7, 
9083–9091 (2015). https ://doi.org/10.1039/c4nr0 5742b 
 21. C. Zhang, C. Li, Y. Liu, J. Zhang, C. Bao et al., Gold nanoclus-
ters-based nanoprobes for simultaneous fluorescence imaging 
and targeted photodynamic therapy with superior penetration 
and retention behavior in tumors. Adv. Funct. Mater. 25, 
1314–1325 (2015). https ://doi.org/10.1002/adfm.20140 3095
 22. D. Pissuwan, T. Niidome, M.B. Cortie, The forthcoming 
applications of gold nanoparticles in drug and gene delivery 
systems. J. Control. Release 149, 65–71 (2011). https ://doi.
org/10.1016/j.jconr el.2009.12.006
 23. J.C. Fraire, G. Houthaeve, J. Liu, L. Raes, L. Vermeulen et al., 
Vapor nanobubble is the more reliable photothermal mecha-
nism for inducing endosomal escape of siRNA without dis-
turbing cell homeostasis. J. Control. Release 319, 262–275 
(2020). https ://doi.org/10.1016/j.jconr el.2019.12.050
 24. L.M.P. Vermeulen, J.C. Fraire, L. Raes, E. De Meester, S. De 
Keulenaer et al., Photothermally triggered endosomal escape 
and its influence on transfection efficiency of gold-function-
alized JetPEI/pDNA nanoparticles. Int. J. Mol. Sci. 19, 2400 
(2018). https ://doi.org/10.3390/ijms1 90824 00
 25. M.P. Stewart, A. Sharei, X. Ding, G. Sahay, R. Langer, K.F. 
Jensen, In vitro and ex vivo strategies for intracellular deliv-
ery. Nature 538, 183–192 (2016). https ://doi.org/10.1038/natur 
e1976 4
 26. P. Aksoy, B.A. Aksoy, E. Czech, J. Hammerbacher, Viable 
and efficient electroporation-based genetic manipulation of 
unstimulated human T cells. BioRxiv (2019). https ://doi.
org/10.1101/46624 3
 27. T. DiTommaso, J.M. Cole, L. Cassereau, J.A. Buggé, J.L.S. 
Hanson et al., Cell engineering with microfluidic squeezing 
preserves functionality of primary immune cells in vivo. Proc. 
Natl. Acad. Sci. 115, E10907–E10914 (2018). https ://doi.
org/10.1073/pnas.18096 71115 
 28. M. Zhang, Z. Ma, N. Selliah, G. Weiss, A. Genin, T.H. Fin-
kel, R.Q. Cron, The impact of Nucleofection® on the acti-
vation state of primary human CD4 T cells. J. Immunol. 
Methods 408, 123–131 (2014). https ://doi.org/10.1016/j.
jim.2014.05.014
 29. B.R. Anderson, K. Karikó, D. Weissman, Nucleofection 
induces transient eIF2α phosphorylation by GCN2 and PERK. 
Gene Ther. 20, 136–142 (2013). https ://doi.org/10.1038/
gt.2012.5
 30. L. Liu, C. Johnson, S. Fujimura, F. Teque, J.A. Levy, Transfec-
tion optimization for primary human CD8+ cells. J. Immu-
nol. Methods 372, 22–29 (2011). https ://doi.org/10.1016/j.
jim.2011.06.026
 31. R. Xiong, S.K. Samal, J. Demeester, A.G. Skirtach, S.C.D. 
Smedt, K. Braeckmans, Laser-assisted photoporation: fun-
damentals, technological advances and applications. Adv. 
Phys. X 1, 596–620 (2016). https ://doi.org/10.1080/23746 
149.2016.12284 76
 32. L. Wayteck, R. Xiong, K. Braeckmans, S.C. De Smedt, K. 
Raemdonck, Comparing photoporation and nucleofection for 
delivery of small interfering RNA to cytotoxic T cells. J. Con-
trol. Release 267, 154–162 (2017). https ://doi.org/10.1016/j.
jconr el.2017.08.002
 Nano-Micro Lett.          (2020) 12:185  185  Page 16 of 17
https://doi.org/10.1007/s40820-020-00523-0© The authors
 33. L.E. Barrett, J.-Y. Sul, H. Takano, E.J. Van Bockstaele, P.G. 
Haydon, J.H. Eberwine, Region-directed phototransfection 
reveals the functional significance of a dendritically synthe-
sized transcription factor. Nat. Methods 3, 455–460 (2006). 
https ://doi.org/10.1038/nmeth 885
 34. D.J. Stevenson, F.J. Gunn-Moore, P. Campbell, K. Dholakia, 
Single cell optical transfection. J. Royal Soc. Interface 7, 863–
871 (2010). https ://doi.org/10.1098/rsif.2009.0463
 35. Y. Hosokawa, H. Ochi, T. Iino, A. Hiraoka, M. Tanaka, Pho-
toporation of biomolecules into single cells in living verte-
brate embryos induced by a femtosecond laser amplifier. 
PLoS ONE 6, 0027677 (2011). https ://doi.org/10.1371/journ 
al.pone.00276 77
 36. S. Kalies, T. Birr, D. Heinemann, M. Schomaker, T. Ripken, 
A. Heisterkamp, H. Meyer, Enhancement of extracellular mol-
ecule uptake in plasmonic laser perforation. J. Biophotonics 7, 
474–482 (2014). https ://doi.org/10.1002/jbio.20120 0200
 37. E. Lukianova-Hleb, Y. Hu, L. Latterini, L. Tarpani, S. Lee 
et al., Plasmonic nanobubbles as transient vapor nanobub-
bles generated around plasmonic nanoparticles. ACS Nano 4, 
2109–2123 (2010). https ://doi.org/10.1021/nn100 0222
 38. R. Xiong, K. Raemdonck, K. Peynshaert, I. Lentacker, I. De 
Cock et al., Comparison of gold nanoparticle mediated pho-
toporation: vapor nanobubbles outperform direct heating for 
delivering macromolecules in live cells. ACS Nano 8, 6288–
6296 (2014). https ://doi.org/10.1021/nn501 7742
 39. E. Teirlinck, R. Xiong, T. Brans, K. Forier, J. Fraire et al., 
Laser-induced vapour nanobubbles improve drug diffusion and 
efficiency in bacterial biofilms. Nat. Commun. 9, 4518 (2018). 
https ://doi.org/10.1038/s4146 7-018-06884 -w
 40. J. Liu, R. Xiong, T. Brans, S. Lippens, E. Parthoens et al., 
Repeated photoporation with graphene quantum dots enables 
homogeneous labeling of live cells with extrinsic markers for 
fluorescence microscopy. Light Sci. Appl. 7, 47 (2018). https 
://doi.org/10.1038/s4137 7-018-0048-3
 41. P. Chakravarty, W. Qian, M.A. El-Sayed, M.R. Prausnitz, 
Delivery of molecules into cells using carbon nanoparticles 
activated by femtosecond laser pulses. Nat. Nanotechnol. 5, 
607–611 (2010). https ://doi.org/10.1038/nnano .2010.126
 42. R. Lachaine, C. Boutopoulos, P.-Y. Lajoie, É. Boulais, M. 
Meunier, Rational design of plasmonic nanoparticles for 
enhanced cavitation and cell perforation. Nano Lett. 16, 3187–
3194 (2016). https ://doi.org/10.1021/acs.nanol ett.6b005 62
 43. L. Van Hoecke, L. Raes, S. Stremersch, T. Brans, J.C. Fraire 
et al., Delivery of mixed-lineage kinase domain-like protein by 
vapor nanobubble photoporation induces necroptotic-like cell 
death in tumor cells. Int. J. Mol. Sci. 20, 4254 (2019). https ://
doi.org/10.3390/ijms2 01742 54
 44. L. Raes, C. Van Hecke, J. Michiels, S. Stremersch, J.C. Fraire 
et  al., Gold nanoparticle-mediated photoporation enables 
delivery of macromolecules over a wide range of molecular 
weights in human CD4+ T cells. Crystals 9, 411 (2019). https 
://doi.org/10.3390/cryst 90804 11
 45. R. Xiong, C. Drullion, P. Verstraelen, J. Demeester, A.G. Skirt-
ach, Fast spatial-selective delivery into live cells. J. Control. 
Release 266, 198–204 (2017). https ://doi.org/10.1016/j.jconr 
el.2017.09.033
 46. R. Xiong, P. Verstraelen, J. Demeester, A.G. Skirtach, J.-P. 
Timmermans et al., Selective labeling of individual neurons 
in dense cultured networks with nanoparticle-enhanced pho-
toporation. Front. Cell. Neurosci. 12, 00080 (2018). https ://
doi.org/10.3389/fncel .2018.00080 
 47. R.T. Abraham, A. Weiss, Jurkat T cells and development of 
the T-cell receptor signalling paradigm. Nat. Rev. Immunol. 
4, 301 (2004). https ://doi.org/10.1038/nri13 30
 48. C.P.M. Duong, J.A. Westwood, C.S.M. Yong, A. Murphy, 
C. Devaud et al., Engineering T cell function using chimeric 
antigen receptors identified using a DNA library approach. 
PLoS ONE 8, 0063037 (2013). https ://doi.org/10.1371/journ 
al.pone.00630 37
 49. K.T. Roybal, L.J. Rupp, L. Morsut, W.J. Walker, K.A. 
McNally, J.S. Park, W.A. Lim, Precision tumor recognition by 
T cells with combinatorial antigen-sensing circuits. Cell 164, 
770–779 (2016). https ://doi.org/10.1016/j.cell.2016.01.011
 50. J. Rydzek, T. Nerreter, H. Peng, S. Jutz, J. Leitner et al., Chi-
meric antigen receptor library screening using a novel NF-κB/
NFAT reporter cell platform. Mol. Ther. 27, 287–299 (2019). 
https ://doi.org/10.1016/j.ymthe .2018.11.015
 51. H. Köksal, E. Baken, D.J. Warren, G.Å. Løset, E.M. Inder-
berg, S. Wälchli, Chimeric antigen receptor preparation from 
hybridoma to T-cell expression. Antib. Ther. 2, 56–63 (2019). 
https ://doi.org/10.1093/abt/tbz00 7
 52. D. Bloemberg, T. Nguyen, S. MacLean, A. Zafer, C. Gadoury 
et al., A high-throughput method for characterizing novel 
chimeric antigen receptors in jurkat cells. Mol. Ther. Meth-
ods Clin. Dev. 16, 238–254 (2020). https ://doi.org/10.1016/j.
omtm.2020.01.012
 53. L. Van Hoecke, S. Van Lint, K. Roose, A. Van Parys, P. Van-
denabeele et al., Treatment with mRNA coding for the necrop-
tosis mediator MLKL induces antitumor immunity directed 
against neo-epitopes. Nat. Commun. 9, 3417 (2018). https ://
doi.org/10.1038/s4146 7-018-05979 -8
 54. D. Wang, P. Cheng, X. Quan, Photothermal nanobubble nucle-
ation on a plasmonic nanoparticle: A 3D lattice Boltzmann 
simulation. Int. J. Heat Mass Transf. 140, 786–797 (2019). 
https ://doi.org/10.1016/j.ijhea tmass trans fer.2019.05.096
 55. R. Xiong, F. Joris, S. Liang, R. De Rycke, S. Lippens et al., 
Cytosolic delivery of nanolabels prevents their asymmet-
ric inheritance and enables extended quantitative in vivo 
cell imaging. Nano Lett. 16, 5975–5986 (2016). https ://doi.
org/10.1021/acs.nanol ett.6b014 11
 56. M. MacKay, E. Afshinnekoo, J. Rub, C. Hassan, M. Khunte 
et al., The therapeutic landscape for cells engineered with chi-
meric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020). 
https ://doi.org/10.1038/s4158 7-019-0329-2
 57. P. Vormittag, R. Gunn, S. Ghorashian, F.S. Veraitch, A guide 
to manufacturing CAR T cell therapies. Curr. Opin. Bio-
technol. 53, 164–181 (2018). https ://doi.org/10.1016/j.copbi 
o.2018.01.025
Nano-Micro Lett.          (2020) 12:185  Page 17 of 17   185 
1 3
 58. S.L. Maude, N. Frey, P.A. Shaw, R. Aplenc, D.M. Barrett 
et al., Chimeric antigen receptor T cells for sustained remis-
sions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014). 
https ://doi.org/10.1056/NEJMo a1407 222
 59. E.A. Stadtmauer, J.A. Fraietta, M.M. Davis, A.D. Cohen, K.L. 
Weber, CRISPR-engineered T cells in patients with refractory 
cancer. Science 367, eaba7365 (2020). https ://doi.org/10.1126/
scien ce.aba73 65
 60. D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenson, Y.K. Cui, 
C. Delbrook et al., T cells expressing CD19 chimeric antigen 
receptors for acute lymphoblastic leukaemia in children and 
young adults: a phase 1 dose-escalation trial. Lancet 385, 517–
528 (2015). https ://doi.org/10.1016/S0140 -6736(14)61403 -3
 61. M. Moenner, E. Hatzi, J. Badet, Secretion of ribonucleases by 
normal and immortalized cells grown in serum-free culture 
conditions. Vitro Cell. Dev. Biol. Anim. 33, 553–561 (1997). 
https ://doi.org/10.1007/s1162 6-997-0098-y
 62. A.A. Davis, M.J. Farrar, N. Nishimura, M.M. Jin, C.B. Schaf-
fer, Optoporation and genetic manipulation of cells using fem-
tosecond laser pulses. Biophys. J. 105, 862–871 (2013). https 
://doi.org/10.1016/j.bpj.2013.07.012
 63. A. Sharei, R. Poceviciute, E.L. Jackson, N. Cho, S. Mao et al., 
Plasma membrane recovery kinetics of a microfluidic intracel-
lular delivery platform. Integr. Biol. 6, 470–475 (2014). https 
://doi.org/10.1039/c3ib4 0215k 
 64. W.P.R. Verdurmen, R. Wallbrecher, S. Schmidt, J. Eilander, 
P. Bovee-Geurts et al., Cell surface clustering of heparan sul-
fate proteoglycans by amphipathic cell-penetrating peptides 
does not contribute to uptake. J. Control. Release 170, 83–91 
(2013). https ://doi.org/10.1016/j.jconr el.2013.05.001
 65. B.R. Olden, Y. Cheng, J.L. Yu, S.H. Pun, Cationic polymers 
for non-viral gene delivery to human T cells. J. Control. 
Release 282, 140–147 (2018). https ://doi.org/10.1016/j.jconr 
el.2018.02.043
 66. Y. Zhao, E. Moon, C. Carpenito, C.M. Paulos, X. Liu et al., 
Multiple injections of electroporated autologous T cells 
expressing a chimeric antigen receptor mediate regression 
of human disseminated tumor. Cancer Res. 70, 9053–9061 
(2010). https ://doi.org/10.1158/0008-5472.CAN-10-2880
 67. Y. Zhao, Z. Zheng, C.J. Cohen, L. Gattinoni, D.C. Palmer, N.P. 
Restifo, S.A. Rosenberg, R.A. Morgan, High-efficiency trans-
fection of primary human and mouse T lymphocytes using 
RNA electroporation. Mol. Ther. 13, 151–159 (2006). https ://
doi.org/10.1016/j.ymthe .2005.07.688
 68. S.H. Yoon, J.M. Lee, H.I. Cho, E.K. Kim, H.S. Kim, M.Y. 
Park, T.G. Kim, Adoptive immunotherapy using human 
peripheral blood lymphocytes transferred with RNA encoding 
Her-2/neu-specific chimeric immune receptor in ovarian can-
cer xenograft model. Cancer Gene Ther. 16, 489–497 (2009). 
https ://doi.org/10.1038/cgt.2008.98
 69. D.A. Mitchell, I. Karikari, X. Cui, W. Xie, R. Schmittling, J.H. 
Sampson, Selective modification of antigen-specific T cells by 
RNA electroporation. Hum. Gene Ther. 19, 511–521 (2008). 
https ://doi.org/10.1089/hum.2007.115
 70. J.A. Jarrell, A.A. Twite, K.H.W.J. Lau, M.N. Kashani, A.A. 
Lievano et al., Intracellular delivery of mRNA to human pri-
mary T cells with microfluidic vortex shedding. Sci. Rep. 9, 
3214 (2019). https ://doi.org/10.1038/s4159 8-019-40147 -y
 71. Y. Peng, D.A. Martin, J. Kenkel, K. Zhang, C.A. Ogden, 
K.B. Elkon, Innate and adaptive immune response to apop-
totic cells. J. Autoimmun. 29, 303–309 (2007). https ://doi.
org/10.1016/j.jaut.2007.07.017
